Comparative analysis of symptom profile and risk of death associated with infection by SARS‐CoV‐2 and its variants in Hong Kong

Abstract

The recurrent multiwave nature of coronavirus disease 2019 (COVID‐19) necessitates updating its symptomatology. We characterize the effect of variants on symptom presentation, identify the symptoms predictive and protective of death, and quantify the effect of vaccination on symptom development. With the COVID‐19 cases reported up to August 25, 2022 in Hong Kong, an iterative multitier text‐matching algorithm was developed to identify symptoms from free text. Multivariate regression was used to measure associations between variants, symptom development, death, and vaccination status. A least absolute shrinkage and selection operator technique was used to identify a parsimonious set of symptoms jointly associated with death. Overall, 70.9% (54 450/76 762) of cases were symptomatic with 102 symptoms identified. Intrinsically, the wild‐type and delta variant caused similar symptoms among unvaccinated symptomatic cases, whereas the wild‐type and omicron BA.2 subvariant had heterogeneous patterns, with seven symptoms (fatigue, fever, chest pain, runny nose, sputum production, nausea/vomiting, and sore throat) more frequent in the BA.2 cohort. With ≥2 vaccine doses, BA.2 was more likely than delta to cause fever among symptomatic cases. Fever, blocked nose, pneumonia, and shortness of breath remained jointly predictive of death among unvaccinated symptomatic elderly in the wild‐type‐to‐omicron transition. Number of vaccine doses required for reducing occurrence varied by symptoms. We substantiate that omicron has a different clinical presentation compared to previous variants. Syndromic surveillance can be bettered with reduced reliance on symptom‐based case identification, increased weighing on symptoms predictive of death in outcome prediction, individual‐based risk assessment in care homes, and incorporating free‐text symptom reporting.